NO20085302L - Farmasoytisk preparat omfattende Amlodipin og Losartan - Google Patents

Farmasoytisk preparat omfattende Amlodipin og Losartan

Info

Publication number
NO20085302L
NO20085302L NO20085302A NO20085302A NO20085302L NO 20085302 L NO20085302 L NO 20085302L NO 20085302 A NO20085302 A NO 20085302A NO 20085302 A NO20085302 A NO 20085302A NO 20085302 L NO20085302 L NO 20085302L
Authority
NO
Norway
Prior art keywords
losartan
amlodipine
pharmaceutical preparation
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO20085302A
Other languages
English (en)
Norwegian (no)
Inventor
Jong-Soo Woo
Hong Gi Yi
Moon Hyuk Chi
Kyeong Soo Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20085302(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of NO20085302L publication Critical patent/NO20085302L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20085302A 2006-12-08 2008-12-18 Farmasoytisk preparat omfattende Amlodipin og Losartan NO20085302L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060124552A KR101247583B1 (ko) 2006-12-08 2006-12-08 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
PCT/KR2007/006352 WO2008069612A1 (en) 2006-12-08 2007-12-07 Pharmaceutical composition comprising amlodipine and losartan

Publications (1)

Publication Number Publication Date
NO20085302L true NO20085302L (no) 2009-06-17

Family

ID=39492408

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085302A NO20085302L (no) 2006-12-08 2008-12-18 Farmasoytisk preparat omfattende Amlodipin og Losartan

Country Status (20)

Country Link
US (1) US20100233261A1 (zh)
EP (1) EP2037917B1 (zh)
JP (1) JP4995912B2 (zh)
KR (1) KR101247583B1 (zh)
CN (1) CN101472587B (zh)
AU (1) AU2007328630B2 (zh)
BR (1) BRPI0713306A8 (zh)
CA (1) CA2654054C (zh)
EC (1) ECSP088980A (zh)
ES (1) ES2522567T3 (zh)
HK (1) HK1131916A1 (zh)
IL (1) IL195581A (zh)
MX (1) MX2008016099A (zh)
MY (1) MY144857A (zh)
NO (1) NO20085302L (zh)
NZ (1) NZ573223A (zh)
RU (1) RU2401107C2 (zh)
UA (1) UA92641C2 (zh)
WO (1) WO2008069612A1 (zh)
ZA (2) ZA200910116B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ594738A (en) 2009-01-23 2013-11-29 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
TWI503119B (zh) * 2009-01-23 2015-10-11 Hanmi Science Co Ltd 含有氨氯地平（ａｍｌｏｄｉｐｉｎｅ）及洛沙坦（ｌｏｓａｒｔａｎ）之固體藥學組成物及其製造方法
CN101849941B (zh) * 2009-04-02 2012-04-18 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物
CN101849942B (zh) * 2009-04-02 2012-05-23 鲁南制药集团股份有限公司 治疗高血压的药物组合物
UA103688C2 (uk) * 2009-06-30 2013-11-11 Санофі Тверді фармацевтичні композиції з фіксованою дозою, що містять ірбесартан і амлодипін, їх отримання і їх терапевтичне застосування
JP2011136908A (ja) * 2009-12-25 2011-07-14 Kyowa Yakuhin Kogyo Kk アンギオテンシンｉｉ受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンｉｉ受容体拮抗剤の保存安定性向上方法
WO2012055941A1 (en) * 2010-10-27 2012-05-03 Krka,Tovarna Zdravil, D. D., Novo Mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
CN102335172B (zh) * 2011-07-20 2012-12-12 海南锦瑞制药股份有限公司 一种氨氯地平与氯沙坦钾药用组合物及其制备方法
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR20150078215A (ko) * 2013-12-30 2015-07-08 (주) 드림파마 에프로사탄 및 암로디핀을 포함하는 복합제제 및 이의 제조방법
KR102369607B1 (ko) * 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물
KR101914930B1 (ko) * 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
KR101750689B1 (ko) * 2015-09-15 2017-06-26 주식회사 종근당 약제학적 복합제제
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
CN110215455A (zh) * 2019-03-26 2019-09-10 山东省药学科学院 一种用于降血压的药物配方
CN112274490B (zh) * 2020-11-19 2022-11-22 四川尚锐生物医药有限公司 一种氨氯地平氯沙坦钾复方组合物的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2257946A1 (en) * 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
CA2420844A1 (en) * 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
US20040137062A1 (en) * 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
JP2007528349A (ja) * 2003-01-27 2007-10-11 ハンミ ファーム． シーオー．， エルティーディー． 高い安定性を有する無定形アムロジピンカムシレート、その製造方法及びこれを含む経口投与用組成物
BRPI0406987A (pt) * 2003-01-31 2006-01-10 Sankyo Co Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral
AR043395A1 (es) * 2003-02-28 2005-07-27 Recordati Ireland Ltd Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DK1814527T4 (da) * 2004-11-05 2020-12-07 Boehringer Ingelheim Int Dobbeltlagstablet omfattende telmisartan og amlodipin
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Also Published As

Publication number Publication date
EP2037917B1 (en) 2014-10-08
RU2401107C2 (ru) 2010-10-10
ES2522567T3 (es) 2014-11-17
NZ573223A (en) 2012-07-27
MX2008016099A (es) 2009-01-19
JP4995912B2 (ja) 2012-08-08
BRPI0713306A2 (pt) 2012-04-17
AU2007328630B2 (en) 2010-03-11
BRPI0713306A8 (pt) 2016-06-07
US20100233261A1 (en) 2010-09-16
KR101247583B1 (ko) 2013-03-26
CN101472587B (zh) 2013-11-20
CA2654054A1 (en) 2008-06-12
EP2037917A4 (en) 2010-08-04
UA92641C2 (ru) 2010-11-25
MY144857A (en) 2011-11-30
CA2654054C (en) 2013-01-08
ZA200810116B (en) 2010-07-28
CN101472587A (zh) 2009-07-01
IL195581A (en) 2015-08-31
KR20080052852A (ko) 2008-06-12
RU2008150477A (ru) 2010-06-27
JP2009544752A (ja) 2009-12-17
IL195581A0 (en) 2009-09-01
AU2007328630A1 (en) 2008-06-12
ECSP088980A (es) 2009-02-27
EP2037917A1 (en) 2009-03-25
HK1131916A1 (en) 2010-02-12
ZA200910116B (en) 2010-07-28
WO2008069612A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
NO20085302L (no) Farmasoytisk preparat omfattende Amlodipin og Losartan
IL259851A (en) Compounds and methods of inhibiting antidepressant nhe mediator in the treatment of disorders associated with fluid retention or overload of salts and gastrointestinal disorders
WO2010066749A3 (en) Ulipristal acetate tablets
JP2007169302A5 (zh)
WO2009144550A3 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
WO2009081174A3 (en) Anti - retroviral combination
WO2012016703A3 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
WO2012016695A3 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
IL212008A0 (en) Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules
WO2009118359A3 (en) Capsule for the prevention of cardiovascular diseases
JP2009537554A5 (zh)
WO2010038237A3 (en) Compositions exhibiting delayed transit through the gastrointestinal tract
CY1114933T1 (el) Στερεες φαρμακευτικες συνθεσεις σταθερης δοσης περιεχουσες ιρβεσαρτανη και αμλοδιπινη, η παρασκευη τους και η θεραπευτικη εφαρμογη τους
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007078271A3 (en) Lansoprazole orally disintegrating tablets
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
MX2009011999A (es) Extruidos con enmascaramiento del sabor mejorado.
WO2007075980A3 (en) Lansoprazole orally disintegrating tablets
EP2366393A3 (en) Roflumilast for the treatment of pulmonary hypertension
WO2007007182A3 (en) Solid and liquid dosage forms of an antiepileptic agent
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
ITFI20080016A1 (it) Formulazioni farmaceutiche orali contenenti gliclazide.
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
ITBO20070186A1 (it) Confezione per confetti, caramelle e simili
WO2008147169A8 (es) Microemolsion conteniendo pirfenidona

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: TANDBERGS PATENTKONTOR AS, POSTBOKS

FC2A Withdrawal, rejection or dismissal of laid open patent application